Desmoplastic Infantile Astrocytoma Treatment
For infants under 24 months with desmoplastic infantile astrocytoma, maximal safe surgical resection is the primary and often sole treatment required, with observation alone appropriate even after incomplete resection given the tumor's WHO Grade I classification and generally favorable prognosis.
Surgical Approach
Pursue maximal safe resection as the definitive treatment. Total or near-total resection should be the goal, but the benign nature of these tumors means that subtotal resection does not mandate additional therapy 1, 2. These are WHO Grade I tumors despite their often large size and aggressive radiological appearance 3.
Key Surgical Considerations:
- Tumor characteristics: Expect large volumes (average 212 cm³), predominantly cystic components, dural attachment, and potential vascular encasement 2
- Surgical challenges: These tumors can be technically demanding due to size and vascular involvement, particularly in neonates
- Blood loss risk: Significant intraoperative hemorrhage is a major concern given the patient's small blood volume 2
Post-Resection Management
Adopt a surveillance strategy after initial surgery, regardless of extent of resection. The evidence strongly supports observation even with residual disease:
- Spontaneous regression: Residual tumors may spontaneously regress without intervention 4
- Stable disease: Many residual tumors remain stable long-term without treatment 4, 2
- Reoperation: If progression occurs or seizures persist from residual tumor, repeat surgery is the first-line option—not chemotherapy or radiation 2
Surveillance Protocol:
- Serial MRI monitoring at regular intervals
- Clinical assessment for seizure control and developmental milestones
- Long-term follow-up warranted given occasional late progression 4
Adjuvant Therapy Indications (Rare)
Reserve chemotherapy exclusively for unresectable or disseminated cases. Chemotherapy has shown mixed results and should not be used routinely 2.
Specific scenarios requiring chemotherapy:
- Leptomeningeal dissemination (occurs in ~2% of cases) 1, 2
- Multifocal lesions that are unresectable and symptomatic
- Progressive disease after multiple surgical attempts when further resection is not feasible
Avoid radiation therapy in this age group (under 24 months) due to significant risk of neurocognitive injury and developmental impairment. The NCCN guidelines emphasize avoiding RT in children <3 years when possible 5.
Prognostic Factors and Monitoring
Favorable Overall Prognosis:
- Mean progression-free survival: 331.7 months
- Mean overall survival: 379.8 months
- Recurrence rate: only 6.2% 1
High-Risk Features Requiring Closer Surveillance:
- Ki-67 index >20%: Significantly associated with recurrence risk (p=0.03) 1
- Multifocal lesions: Significantly associated with recurrence or dissemination (p<0.05) 1
- BRAF mutations: Present in one-third of cases, with possible correlation to recurrence 1
- Suprasellar location: Higher progression risk after subtotal resection 4
Critical Pitfall:
Do not be misled by aggressive radiological appearance. Despite large size, mass effect, and contrast enhancement, these remain WHO Grade I tumors with excellent prognosis. Avoid overtreatment with chemotherapy or radiation based solely on imaging characteristics 3.
Special Consideration: Multifocal Disease
For patients presenting with multiple intracranial or intraspinal lesions 6:
- Resect the most symptomatic lesion
- Observe other sites, as spontaneous regression of non-resected lesions has been documented 4, 6
- Reserve systemic therapy only for progressive, symptomatic multifocal disease unamenable to surgery
The key principle: surgical resection when feasible, observation for residual/multifocal disease, and chemotherapy only as a last resort for truly unresectable progressive disease.